Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Nat Commun ; 6: 7419, 2015 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-26080861

RESUMEN

Currently available human tumour cell line panels consist of a small number of lines in each lineage that generally fail to retain the phenotype of the original patient tumour. Here we develop a cell culture medium that enables us to routinely establish cell lines from diverse subtypes of human ovarian cancers with >95% efficiency. Importantly, the 25 new ovarian tumour cell lines described here retain the genomic landscape, histopathology and molecular features of the original tumours. Furthermore, the molecular profile and drug response of these cell lines correlate with distinct groups of primary tumours with different outcomes. Thus, tumour cell lines derived using this methodology represent a significantly improved platform to study human tumour pathophysiology and response to therapy.


Asunto(s)
Carcinoma/patología , Línea Celular Tumoral , Neoplasias Ováricas/patología , Cisplatino , Medios de Cultivo , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Perfilación de la Expresión Génica , Xenoinjertos , Humanos , Paclitaxel , Fenotipo
2.
PLoS One ; 8(11): e80314, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24303006

RESUMEN

The potential role of the cell-of-origin in determining the tumor phenotype has been raised, but not adequately examined. We hypothesized that distinct cells-of-origin may play a role in determining ovarian tumor phenotype and outcome. Here we describe a new cell culture medium for in vitro culture of paired normal human ovarian (OV) and fallopian tube (FT) epithelial cells from donors without cancer. While these cells have been cultured individually for short periods of time, to our knowledge this is the first long-term culture of both cell types from the same donors. Through analysis of the gene expression profiles of the cultured OV/FT cells we identified a normal cell-of-origin gene signature that classified primary ovarian cancers into OV-like and FT-like subgroups; this classification correlated with significant differences in clinical outcomes. The identification of a prognostically significant gene expression signature derived solely from normal untransformed cells is consistent with the hypothesis that the normal cell-of-origin may be a source of ovarian tumor heterogeneity and the associated differences in tumor outcome.


Asunto(s)
Células Epiteliales/metabolismo , Trompas Uterinas/metabolismo , Perfilación de la Expresión Génica , Neoplasias Ováricas/genética , Ovario/metabolismo , Transcriptoma , Animales , Línea Celular Transformada , Modelos Animales de Enfermedad , Femenino , Xenoinjertos , Humanos , Ratones , Neoplasias Ováricas/mortalidad , Neoplasias Ováricas/patología , Cultivo Primario de Células , Pronóstico
3.
Cancer Res ; 71(7): 2686-96, 2011 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-21447744

RESUMEN

NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patient-derived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC.


Asunto(s)
Diferenciación Celular/genética , Neoplasias del Mediastino/genética , Neoplasias Nasofaríngeas/genética , Proteínas Nucleares/genética , Proteínas de Fusión Oncogénica/genética , Acetilación , Animales , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , Niño , Femenino , Técnicas de Silenciamiento del Gen , Inhibidores de Histona Desacetilasas/farmacología , Histonas/genética , Histonas/metabolismo , Humanos , Ácidos Hidroxámicos/farmacología , Neoplasias del Mediastino/tratamiento farmacológico , Neoplasias del Mediastino/metabolismo , Neoplasias del Mediastino/patología , Ratones , Ratones Desnudos , Neoplasias Nasofaríngeas/tratamiento farmacológico , Neoplasias Nasofaríngeas/metabolismo , Neoplasias Nasofaríngeas/patología , Proteínas de Neoplasias , Proteínas Nucleares/biosíntesis , Proteínas Oncogénicas/genética , Proteínas de Fusión Oncogénica/biosíntesis , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/genética , Transfección , Trasplante Heterólogo , Vorinostat
4.
Sci Signal ; 3(130): ra52, 2010 Jul 13.
Artículo en Inglés | MEDLINE | ID: mdl-20628156

RESUMEN

The Keap1-Nrf2-ARE signaling pathway elicits an adaptive response for cell survival after endogenous and exogenous stresses, such as inflammation and carcinogens, respectively. Keap1 inhibits the transcriptional activation activity of Nrf2 (p45 nuclear factor erythroid-derived 2-related factor 2) in unstressed cells by facilitating its degradation. Through transcriptional analyses in Keap1- or Nrf2-disrupted mice, we identified interactions between the Keap1-Nrf2-ARE and the Notch1 signaling pathways. We found that Nrf2 recognized a functional antioxidant response element (ARE) in the promoter of Notch1. Notch1 regulates processes such as proliferation and cell fate decisions. We report a functional role for this cross talk between the two pathways and show that disruption of Nrf2 impeded liver regeneration after partial hepatectomy and was rescued by reestablishment of Notch1 signaling.


Asunto(s)
Regeneración Hepática , Factor 2 Relacionado con NF-E2/fisiología , Receptor Notch1/metabolismo , Transducción de Señal , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Animales , Antioxidantes , Proteínas del Citoesqueleto/metabolismo , Hepatectomía , Proteína 1 Asociada A ECH Tipo Kelch , Ratones , Ratones Noqueados , Factor 2 Relacionado con NF-E2/genética , Regiones Promotoras Genéticas , Receptor Cross-Talk , Elementos de Respuesta
5.
Am J Clin Pathol ; 134(1): 36-41, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20551264

RESUMEN

Human papillomavirus (HPV) testing is routinely performed on oropharyngeal carcinomas. We compared the Access Genetics (Minneapolis, MN) polymerase chain reaction (PCR) assay (AGPCR), DNA-DNA in situ hybridization (ISH; Ventana, Tucson, AZ), and HPV-16 E7 PCR amplification in consecutively accessioned oropharyngeal cancers. We tested 126 cases by both PCR methods; 102 were positive by either for a maximum positive rate (MPR) of 81.0%. Relative to the MPR, the sensitivities of AGPCR and E7 PCR were 90.2% and 72.5%, respectively. Of 17 AGPCR+ cases tested by ISH, 14/14 unequivocally positive/negative were concordant. All cases (97/97) positive by either PCR assay were positive for p16. There was no relationship between level of histologic differentiation and HPV status. ISH and AGPCR have comparable performance for the detection of HPV in oropharyngeal carcinomas. PCR is a suitable and economical assay that is comparable to ISH in sensitivity and may provide logistical advantages relative to ISH for assessing HPV status in oropharyngeal malignancies. However, it is imperative that appropriate sensitivity controls be in place for such assays.


Asunto(s)
Carcinoma de Células Escamosas/virología , Neoplasias Orofaríngeas/virología , Orofaringe/virología , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/virología , Reacción en Cadena de la Polimerasa/métodos , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Escamosas/patología , Inhibidor p16 de la Quinasa Dependiente de Ciclina , ADN de Neoplasias/análisis , ADN Viral/análisis , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Técnicas para Inmunoenzimas , Hibridación in Situ , Proteínas de Neoplasias/metabolismo , Neoplasias Orofaríngeas/patología , Orofaringe/patología , Papillomaviridae/genética , Infecciones por Papillomavirus/patología , Reacción en Cadena de la Polimerasa/economía , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados
6.
PLoS One ; 5(1): e8927, 2010 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-20126631

RESUMEN

The taurine amino-acid derivative, taurolidine, bis-(1,1-dioxoperhydro-1,2,4-thiabiazinyl-4)methane, shows broad antibacterial action against gram-positive and gram-negative bacteria, mycobacteria and some clinically relevant fungi. It inhibits, in vitro, the adherence of Escherichia coli and Staphylococcus aureus to human epithelial and fibroblast cells. Taurolidine is unstable in aqueous solution and breaks down into derivatives which are thought to be responsible for the biological activity. To understand the taurolidine antibacterial mechanism of action, we provide the experimental single crystal X-ray diffraction results together with theoretical methods to characterize the hydrolysis/decomposition reactions of taurolidine. The crystal structure features two independent molecules linked through intermolecular H-bonds with one of them somewhat positively charged. Taurolidine in a biological environment exists in equilibrium with taurultam derivatives and this is described theoretically as a 2-step process without an energy barrier: formation of cationic taurolidine followed by a nucleophilic attack of O(hydroxyl) on the exocyclic C(methylene). A concerted mechanism describes the further hydrolysis of the taurolidine derivative methylol-taurultam. The interaction of methylol-taurultam with the diaminopimelic NH(2) group in the E. coli bacteria cell wall (peptidoglycan) has a negative DeltaG value (-38.2 kcal/mol) but a high energy barrier (45.8 kcal/mol) suggesting no reactivity. On the contrary, taurolidine docking into E. coli fimbriae protein, responsible for bacteria adhesion to the bladder epithelium, shows it has higher affinity than mannose (the natural substrate), whereas methylol-taurultam and taurultam are less tightly bound. Since taurolidine is readily available because it is administered in high doses after peritonitis surgery, it may successfully compete with mannose explaining its effectiveness against bacterial infections at laparoscopic lesions.


Asunto(s)
Adhesión Bacteriana/efectos de los fármacos , Pared Celular/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Taurina/análogos & derivados , Tiadiazinas/farmacología , Transformación Bacteriana , Modelos Moleculares , Taurina/química , Taurina/farmacología , Tiadiazinas/química
8.
Mol Cell Biol ; 27(20): 7188-97, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17709388

RESUMEN

The NF-E2 p45-related factor 2 (NRF2) and the aryl hydrocarbon receptor (AHR) are transcription factors controlling pathways modulating xenobiotic metabolism. AHR has recently been shown to affect Nrf2 expression. Conversely, this study demonstrates that NRF2 regulates expression of Ahr and subsequently modulates several downstream events of the AHR signaling cascade, including (i) transcriptional control of the xenobiotic metabolism genes Cyp1a1 and Cyp1b1 and (ii) inhibition of adipogenesis in mouse embryonic fibroblasts (MEFs). Constitutive expression of AHR was affected by Nrf2 genotype. Moreover, a pharmacological activator of NRF2 signaling, CDDO-IM {1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole}, induced Ahr, Cyp1a1, and Cyp1b1 transcription in Nrf2+/+ MEFs but not in Nrf2-/- MEFs. Reporter analysis and chromatin immunoprecipitation assay revealed that NRF2 directly binds to one antioxidant response element (ARE) found in the -230-bp region of the promoter of Ahr. Since AHR negatively controls adipocyte differentiation, we postulated that NRF2 would inhibit adipogenesis through the interaction with the AHR pathway. Nrf2-/- MEFs showed markedly accelerated adipogenesis upon stimulation, while Keap1-/- MEFs (which exhibit higher NRF2 signaling) differentiated slowly compared to their congenic wild-type MEFs. Ectopic expression of Ahr and dominant-positive Nrf2 in Nrf2-/- MEFs also substantially delayed differentiation. Thus, NRF2 directly modulates AHR signaling, highlighting bidirectional interactions of these pathways.


Asunto(s)
Adipogénesis/fisiología , Regulación de la Expresión Génica , Factor 2 Relacionado con NF-E2/metabolismo , Receptores de Hidrocarburo de Aril/metabolismo , Transducción de Señal/fisiología , Proteínas Adaptadoras Transductoras de Señales/genética , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Adipocitos/fisiología , Animales , Diferenciación Celular/fisiología , Células Cultivadas , Proteínas del Citoesqueleto/genética , Proteínas del Citoesqueleto/metabolismo , Fibroblastos/citología , Fibroblastos/fisiología , Genes Reporteros , Proteína 1 Asociada A ECH Tipo Kelch , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Factor 2 Relacionado con NF-E2/genética , Regiones Promotoras Genéticas , Receptores de Hidrocarburo de Aril/genética , Transcripción Genética
9.
J Steroid Biochem Mol Biol ; 103(3-5): 213-21, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17218093

RESUMEN

Three new Vitamin D analogs 3-5 incorporating a -CHF(2) group as an -OH surrogate have been prepared. Two of these new analogs (3 and 5) are strongly antiproliferative toward murine keratinocytes and are approximately 50 times less calciuric in vivo than the natural hormone calcitriol. The transcriptional activity of the 25-CHF(2) analog 3 is higher than that of the 1-CHF(2) analog 4.


Asunto(s)
Productos Biológicos/química , Productos Biológicos/farmacología , Diseño de Fármacos , Flúor/química , Hormonas/química , Vitamina D/análogos & derivados , Animales , Productos Biológicos/síntesis química , Calcio/orina , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Hormonas/síntesis química , Hormonas/farmacología , Metilación , Ratones , Estructura Molecular , Ratas , Vitamina D/síntesis química , Vitamina D/química , Vitamina D/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...